Physician profile
Mandy M Wright
NPI 1891247748
$1,726.20
in general payments reported to CMS, 2019-2025
29 companies · $391 in 2025
The $391 reported for 2025 was more than what a typical Gerontology (Nurse Practitioner) provider received nationally (typical 2025 total: $180).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $441 · 2022: $343 · 2023: $324 · 2024: $227 · 2025: $391.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $942.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $941.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon US, LLC | $368.27 | 2021-2024 | Echelon; Endopath, Echelon Endopath |
| Abbvie INC. | $195.00 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $142.92 | 2021-2023 | Gattex |
| Janssen Pharmaceuticals, INC | $138.43 | 2021-2022 | |
| Insmed, INC. | $90.12 | 2024-2025 | Arikayce, Brinsupri |
| Calliditas Therapeutics US INC. | $88.10 | 2024-2025 | Tarpeyo |
| Aimmune Therapeutics, INC. | $86.32 | 2024-2025 | Vowst |
| Merck Sharp & Dohme LLC | $68.97 | 2024-2025 | Zerbaxa, Dificid, Recarbrio |
| Tela Bio, INC. | $55.12 | 2021 | |
| Shionogi INC | $51.03 | 2024-2025 | Fetroja |
| Depuy Synthes Sales INC. | $43.75 | 2021 | |
| Kci USA, INC. | $38.44 | 2021-2023 | Prevena Restor Bellaform |
| La Jolla Pharmaceutical Company | $30.70 | 2024 | Xerava |
| Otsuka America Pharmaceutical, INC. | $28.88 | 2025 | Jynarque |
| Cardiva Medical, INC. | $28.65 | 2023 | Cardiva Vascade 6/7f Vcs |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $25.02 | 2025 | Ibsrela |
| Tetraphase Pharmaceuticals, INC. | $24.69 | 2025 | |
| Ambu INC. | $24.40 | 2022 | |
| Endologix LLC | $24.06 | 2024 | Torus Stent Graft System, Endocross Device |
| Acacia Pharma INC | $23.42 | 2021 | |
| Paratek Pharmaceuticals, INC. | $23.01 | 2025 | Nuzyra |
| Boston Scientific Corporation | $22.33 | 2023 | Varithena Administration Pack |
| Inari Medical, INC. | $22.30 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Silk Road Medical, INC. | $17.96 | 2023 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent |
| Lemaitre Vascular, INC. | $15.53 | 2023 | Artegraft Vascular Graft |
| Ferring Pharmaceuticals INC. | $13.29 | 2024 | Rebyota |
| Insulet Corporation | $13.00 | 2022 | |
| Pfizer INC. | $11.33 | 2021 | |
| Stryker Corporation | $11.16 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mandy Wright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.